Predictive Oncology (POAI) Director Awarded 64,680 RSUs; Vesting Date Announced

Rhea-AI Filing Summary

Predictive Oncology Inc. (POAI) reported a non‑derivative grant to director Matthew Hawryluk consisting of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts into one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, contingent on continued service through that date. After the grant, Mr. Hawryluk is recorded as beneficially owning 74,168 shares of common stock. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 09/11/2025.

Positive

• 64,680 RSUs granted to a director, aligning his financial incentives with shareholder value upon vesting
• Clear vesting date (October 31, 2025) provides transparency on when shares may be issued

Negative

• Potential dilution from 64,680 RSUs when settled into shares
• Single full‑vesting date (not staggered) concentrates vesting risk and may offer weaker retention signaling than multi‑year vesting

Insights

Securities Analyst

TL;DR Director received 64,680 RSUs vesting 10/31/2025, aligning compensation with shareholder value.

The grant of 64,680 restricted stock units to a company director is a routine equity compensation event that ties the director's incentives to future share performance. The units vest in full on October 31, 2025, subject to continued service, which may help align long‑term interests but will increase potential shares outstanding when settled. The filing shows beneficial ownership rising to 74,168 shares after the grant. No derivative securities or cash purchase was reported, and the transaction code indicates an award rather than a purchase.

Corporate Governance Expert

TL;DR This appears to be a standard service‑based RSU grant to a director with a single vesting date.

The disclosure is straightforward: the RSUs vest in full on a fixed future date subject to continued service, a common design for director compensation. From a governance perspective, single‑date full vesting is less gradual than multi‑year vesting schedules and concentrates vesting risk into one date. The Form 4 provides clear quantities and ownership post‑grant but does not state the grant’s rationale, award program, or whether it reflects a one‑time grant or part of an ongoing plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hawryluk Matthew

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		64,680(1)	A	$0.00	74,168	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did POAI report in the Form 4 filed for Matthew Hawryluk?

The Form 4 reports a grant of 64,680 restricted stock units (RSUs) to director Matthew Hawryluk on 09/09/2025, vesting in full on October 31, 2025.

How many shares will Matthew Hawryluk beneficially own after the reported transaction?

After the reported RSU grant, the filing shows Mr. Hawryluk beneficially owning 74,168 shares of common stock.

Do the RSUs have an exercise price or purchase cost?

The transaction is coded as an award with a reported price of $0.00, indicating these RSUs were granted rather than purchased.

When do the RSUs vest and what is the vesting condition?

The RSUs are set to vest in full on October 31, 2025, subject to the reporting person’s continued service through that date.

Was the Form 4 signed by the reporting person?

The Form 4 shows a signature by an attorney‑in‑fact (Josh Blacher) on behalf of the reporting person dated 09/11/2025.